Eli Lilly Q1 Revenue Soars 45% as Mounjaro and Zepbound Drive Record Growth
Eli Lilly reported exceptional Q1 2025 financial results, with revenue reaching $12.73 billion - a 45% increase year-over-year. This growth was primarily driven by strong sales of Mounjaro and Zepbound, their flagship weight-loss and diabetes medications.
Key Financial Highlights:
- U.S. revenue: $8.49 billion (up 49%)
- Global volume growth: 53%
- Net income: $2.76 billion (up 23%)
- Non-GAAP EPS: $3.34
The company saw significant international growth, with revenue outside the U.S. increasing by 38%. This was boosted by Mounjaro demand and a one-time $370 million benefit from Jardiance through a restructured collaboration with Boehringer Ingelheim.
Pipeline Development: Eli Lilly announced positive Phase 3 trial results for orforglipron, their oral GLP-1 agonist for Type 2 diabetes and obesity treatment. This marks the first successful trial of seven planned late-stage studies, positioning the company for continued growth in the metabolic treatment market.
Manufacturing Expansion: To meet increasing demand, CEO David Ricks confirmed plans to construct four new production facilities globally, ensuring stable supply for Mounjaro and Zepbound prescriptions.
Future Outlook: The company maintains its full-year 2025 revenue guidance between $58-61 billion, demonstrating confidence in sustained growth. With strong product performance and promising pipeline developments, particularly in oral weight-loss medications, Eli Lilly continues to strengthen its position in the pharmaceutical industry.
The stock (LLY) responded positively to these results, rising 1.55% and reinforcing investor confidence in the company's long-term growth strategy.